



Approved for use through 6/30/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10774,332
		Filing Date	02/06/2004
		First Named Inventor	Kotov
		Art Unit	1617
		Examiner Name	Unknown
Sheet 1 of 1	Attorney Docket Number	67183/04-006	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA		US- 4,452,773	06-05-1984	MOLDAY	
AB		US- 5,521,289	05-28-1996	HAINFELD, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code* - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
BA		WO 99/36090	07-22-1999	UNIV JOHN HOPKINS, et al.		
BB		WO 99/04627	02-04-1999	THE AUSTRALIAN UNIVERSITY, et al.		
BC		WO 99/56361	12-17-1998	SABEL, et al.		

Examiner Signature	Date Considered
<i>[Signature]</i>	6-19-07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.  
#384892 v1



PATENT  
Attorney Docket No.: 67183/04-006  
FORM 1449  
Page 1 of 3

<b>FORM PTO-1449 (Modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)	Attorney Docket No.: 67183/04-006	
	Applicant(s): Nicholas A. KOTOV	
	Title: Bioconjugates of nanoparticles as radiopharmaceuticals	
	Serial No.: 10/774,332	Filing Date: 02/06/2004
	Group: 1617	Examiner: Unknown

### U.S. PATENT DOCUMENTS




Examiner Initials		Document No.	Date	Name	Class	Subclass
MS	AA	6,689,338	02/10/2004	Kotov	424	1.69
	AB	6,495,324	12/17/2002	Mirkin et al.	435	6
	AC	6,361,944	03/26/2002	Mirkin et al.	435	6
	AD	6,350,515	02/26/2002	Lawton et al.	428	323
	AE	6,333,110	12/25/2001	Barbera-Guillem	428	402.24
	AF	6,274,323	08/14/2001	Bruchez et al.	435	6
	AG	6,261,779	07/17/2001	Barbera-Guillem et al.	435	6
	AH	6,235,540	05/22/2001	Siiman et al.	436	518
	AI	6,207,392	03/27/2001	Weiss et al.	435	7.1
	AJ	6,114,038	09/05/2000	Castro et al.	428	402.24
	AK	6,048,515	04/11/2000	Kresse et al.	424	9.322
	AL	5,990,479	11/23/1999	Weiss et al.	250	307
V	AM	5,427,767	06/27/1995	Kresse et al.	424	9.32


# FOREIGN PATENT DOCUMENTS

Examiner Initials		Document No.	Date	Name (Inventors)	Class	Translation Yes / No
ABSTRACT ONLY [Signature]	AN	WO 01/33223 A1	10 May 2001	Elais-Sari et al.	G01N 33/543	No
ABSTRACT ONLY	AO	WO 01/19405 A2	22 March 2001	Bahr et al.	A61K 47/48	No
	AP	WO 01/091808 A3	6 December 2001	Kotov	A61K 51/12	
	AQ	WO 00/17656 A1	30 March 2000	Bawendi et al.	G01N 33/58	
	AR	WO 00/17655 A1	30 March 2000	Bawendi et al.	G01N 33/58	
	AS	WO 00/17642 A2 & A3	30 March 2000	Bawendi et al.	G01N 33/53	
	AT	WO 00/17103 A2 & A3	30 March 2000	Bawendi et al.	C01B 33/00	
ABSTRACT ONLY	AU	WO 96/04017	15 February 1996	Kresse et al.	A61K 49/00	No
ABSTRACT ONLY [Signature]	AV	EP 0 516 252 A2	13 April 1992	Kresse et al.	A61K 49/00	No

# OTHER ART

Examiner Initial		(Including Author, Title, Date, Pertinent Pages, Etc.)
[Signature]	AW	PCT International Preliminary Examination Report for PCT/US01/17658, 13 May 2003.

Examiner Initial		(Including Author, Title, Date, Pertinent Pages, Etc.)
	AX	XP-002908597: Shiju, Hiroshi et al. Development of a cancer vaccine: peptides, proteins, and DNA. <i>Cancer Chemother Pharmacol.</i> 46 (Suppl), pp. S77-S82, 2000.
	AY	XP-001006052: Schaertl, Sabine et al. A Novel and Robust Homogeneous Fluorescence-Based Assay Using Nanoparticles for Pharmaceutical Screening and Diagnostics. <i>Journal of Biomolecular Screening.</i> Vol. 5, No. 4, pp. 227-237, 2000.
	AZ	Tiefenauer et al. "Antibody-magnetite nanoparticles: In vitro characterization of a potential tumor specific contrast agent for MRI". <i>Bioconjugate Chem.</i> (1993), 4(5), 347-52.

EXAMINER 	DATE CONSIDERED 6-19-07
---	----------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance. Include copy of this form with next communication to applicant.